Market Overview

UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Celgene Corporation

Share:
Related CELG
Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases
JMP Sees A 'Negative Market Tone' In Biotechnology
Celgene, Juno Will Partner (Investor's Business Daily)

In a report published Friday, Citigroup reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $93.00 to $114.00.

Citigroup noted, “Coming out of Q4:12 earnings Celgene's business continues to perform well and we're bullish on the 2013 outlook and see many ways for Celgene to meet/beat ests. We believe Revlimid sales will continue to grow in 2013 and upside to revs and EPS guidance will be bolstered by: 1) strong Abraxane sales given the recent positive pancreatic data; 2) recent Abraxane NSCLC approval; 3) delayed generic Vidaza; and 4) the remaining ~$1.8B in stock buybacks. Celgene is our top idea for lg cap biotech and we expect positive data from the MM-020 study in March/April and that should drive both upwards revs/EPS revisions in 2014 and beyond and multiple expansion. In addition, upcoming apremilast Ph 3 data in psoriasis in Q1:13 and regulatory filing this year should further drive multiple expansion.”

Celgene Corporation closed on Thursday at $97.49.

Latest Ratings for CELG

DateFirmActionFromTo
Feb 2015JefferiesMaintainsBuy
Jan 2015Deutsche BankMaintainsBuy
Jan 2015CitigroupMaintainsBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (CELG)

Around the Web, We're Loving...

Get Benzinga's Newsletters